Psychiatrictimes

Published September 21, 2026 · Updated September 22, 2026

New Analyses of HLP003 for the Adjunctive Treatment of MDD | Psychiatric Times

Read the full story at Psychiatrictimes

Unlike other psychedelic -derived compounds in development that target treatment-resistant depression, which affects only 20% to 25% of patients with.